Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses

Zapisane w:

Opis bibliograficzny
Wydane w:	bioRxiv (Dec 12, 2024)
1. autor:	Lei, Jonathan T
Kolejni autorzy:	Dobrolecki, Lacey E, Huang, Chen, Srinivasan, Ramakrishnan R, Vasaikar, Suhas V, Lewis, Alaina N, Sallas, Christina, Zhao, Na, Cao, Jin, Landua, John D, Chang In Moon, Liao, Yuxing, Hilsenbeck, Susan G, Osborne, C Kent, Rimawi, Mothaffar F, Ellis, Matthew J, Petrosyan, Varduhi, Wen, Bo, Li, Kai, Saltzman, Alexander B, Jain, Antrix, Malovannaya, Anna, Wulf, Gerburg M, Marangoni, Elisabetta, Li, Shunqiang, Kraushaar, Daniel C, Wang, Tao, Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, Funda, Echeverria, Gloria V, Meenakshi Anurag, Chen, Xi, Welm, Bryan E, Welm, Alana L, Zhang, Bing, Lewis, Michael T
Wydane:	Cold Spring Harbor Laboratory Press
Hasła przedmiotowe:	AstraZeneca AbbVie Inc Pfizer Inc Envigo Seattle Genetics Inc Antagonism Models Experimental research Cancer therapies Cytokeratin Biotechnology Oncology Disease management Breast cancer Transcriptomics Proteomics Royalties Histone deacetylase Stockholders Biomarkers Research funding Licenses Carboplatin Chemotherapy Patients Chemoresistance Fees & charges Xenografts
Dostęp online:	Citation/Abstract Full Text - PDF Full text outside of ProQuest
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Napisz pierwszy komentarz!